Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 2/20 | 0.73 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.73 |
| ▸ | LMNA | P02545 | 1/20 | 0.69 |
| ▸ | MEN1 | O00255 | 3/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | CASR | P41180 | 2/20 | 0.52 |
| ▸ | POLB | P06746 | 2/20 | 0.51 |
| ▸ | TACR1 | P25103 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.49 |
| ▸ | GRIN2A | Q12879 | 2/20 | 0.49 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3670110 | 1.00 | ATM (0.73) | ATML3MBTL1LMNAMEN1KMT2A | |
| SCHEMBL7183804 | 0.86 | LMNA (0.58) | ATML3MBTL1LMNAMEN1KMT2A | |
| SCHEMBL9088417 | 0.86 | LMNA (0.58) | ATML3MBTL1LMNAMEN1KMT2A | |
| SCHEMBL9087458 | 0.86 | LMNA (0.58) | ATML3MBTL1LMNAMEN1KMT2A | |
| SCHEMBL14469670 | 0.85 | ATM (0.57) | ATML3MBTL1LMNAMEN1KMT2A | |
| SCHEMBL24455051 | 0.84 | LMNA (0.70) | ATML3MBTL1LMNAMEN1KMT2A | |
| SCHEMBL29793657 | 0.84 | LMNA (0.70) | ATML3MBTL1LMNAMEN1KMT2A | |
| SCHEMBL14469760 | 0.83 | L3MBTL1 (0.55) | ATML3MBTL1LMNAMEN1KMT2A | |
| SCHEMBL9965797 | 0.82 | ATM (0.67) | ATML3MBTL1MEN1KMT2AALDH1A1 | |
| SCHEMBL15131152 | 0.82 | LMNA (0.56) | ATML3MBTL1LMNAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1884509-B1 | OPTICALLY ACTIVE 3-METHYLCYCLOPENTADECANONE AND METHOD FOR PRODUCING INTERMEDIATE THEREOF | TAKASAGO PERFUMERY CO LTD (JP) | 2013-01-02 | — | — | EP | disclosed |
| US-7728177-B2 | Optically active 3-methylcyclopentadecanone and method for producing intermediate thereof | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2010-06-01 | — | — | US | disclosed |
| US-20090124826-A1 | 2-cyclopentadecen-1-one is subjected to a 1,4-conjugate addition reaction of a methyl group by using a methylated organic metal ( dimethylzinc) in presence of a catalyst (trifluoromethanesulfonic acid, cu salt), an enol anion scavenger(propionic anhydride), a specific optically active phosphoramidite | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2009-05-14 | — | — | US | disclosed |
| EP-1884509-A1 | OPTICALLY ACTIVE 3-METHYLCYCLOPENTADECANONE AND METHOD FOR PRODUCING INTERMEDIATE THEREOF | Takasago International Corporation (JP) | 2008-02-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090124826-A1 | 2-cyclopentadecen-1-one is subjected to a 1,4-conjugate addition reaction of a methyl group by using a methylated organic metal ( dimethylzinc) in presence of a catalyst (trifluoromethanesulfonic acid, cu salt), an enol anion scavenger(propionic anhydride), a specific optically active phosphoramidite | CPN1, CAPN1, MCOLN1 | ATM 4810/4885L3MBTL1 2010/4885LMNA 958/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.